(BW Healthwire)–April 18, 2002—Xencor’s President and CEO, Dr. Bassil Dahiyat Chairs Panel at CALBIOsummit 2002

(BW Healthwire)–March 11, 2002—Xencor President and CEO Presents at SG Cowen Health Care Conference Today at 10:00 am EST

Xencor Expands Protein Optimization Technology To Develop Next-Generation Biotechnology Products (BW Healthwire)–February 20, 2002—Monrovia, CA – February 20, 2002 – Xencor today announced that it has signed licensing agreements with the California Institute of Technology and Pennsylvania State

Syngenta’s Torrey Mesa Research Institute And Xencor Sign Research And License Agreement (BW Healthwire)–January 03, 2002—La Jolla, CA and Monrovia, CA.- January 3, 2002 -Torrey Mesa Research Institute (TMRI), a wholly owned subsidiary of Syngenta (NYSE: SYT), today announced the signing of a three

Xencor Expands Management Team To Lead Drug Discovery And Protein Optimization Programs (BW Healthwire)–October 09, 2001—Xencor today announced that Stephen K. Doberstein, Ph.D. has joined as Vice President, Chemical Biology and Robert E. Pacifici, Ph.D.

Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products Xencor Receives Two Patents For Ultra-Fast Optimization Technology To Create A New Generation Of Biotechnology Products (BW Healthwire)–August 06, 2001—Protein Design Automation™

Xencor Expands Management Team; Leverages $50 Million Series C Financing to Fuel Development Efforts (BW Healthwire)–July 19, 2001—Xencor today announced that E.William Radany, Ph.D. has joined the company as Chief Business Officer and Joyce L. Morrison has joined as Vice President, Intellectual

Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins (BW Healthwire)–June 19, 2001—Paves the Way for Improved Biopharmaceuticals and New Industrial and Agricultural Products Xencor today announced that the company has been awarded a

Xencor Closes $12.3 Million in Financing (BW Healthwire)–June 14, 1999—Xencor Inc. announced the closing of a second round of private equity financing for $12.3 million. This financing was led by Stafford Investments LLC of Chicago, Illinois and will be used to accelerate the research, development

Xencor Co-Founder, Stephen Mayo, Presents Protein Design Automation Results at AAAS Meeting (BW Healthwire)–January 25, 1999—Stephen Mayo Ph.D., Associate Professor of Biology, California Institute of Technology and co-founder of Xencor Inc., presented new results from Protein Design AutomationTM,